Burning Rock (BNR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$73.6M

Revenue (quarter)

$19.9M

Revenue growth (year over year)

−4.22%

Gross profit (trailing twelve months)

$54.8M

Gross margin

74.50%

Net income (trailing twelve months)

−$10.0M

Net income (quarter)

−$2.7M

Net income growth (year over year)

−100.34%

Net margin

−13.54%

Return on equity

−13.11%

EPS (trailing twelve months)

−$0.94

Book value per share

$6.95

P/E (trailing twelve months)

—

Price to book

2.10

Debt to assets

33.78%

Payout ratio

—

Dividend yield

—

Company profile

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

• Is Burning Rock (BNR) profitable?

  No. Burning Rock reported a net loss of $10.0M over the trailing twelve months.

• How much revenue does Burning Rock (BNR) make?

  Burning Rock generated $73.6M in revenue over the trailing twelve months, down 4.22% year over year.

• How do I buy stock in Burning Rock (BNR)?

  BNR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.